Treatment options for esophageal cancer

Murphy, Thomas J.; Ravi, N; Reynolds, John V.

doi:10.1517/14656560802560237

Cited by 9 publications

(5 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 30-year-old woman with a carcinoma of the tongue and undiagnosed Fanconi anemia developed severe mucositis following radiotherapy (Alter et al 2005). Presently, chemotherapy and radiotherapy are the main remedies for treating or down-staging of ESCC patients before surgery with occasional severe side effects (Alter et al 2005;Murphy et al 2008), and it is important to evaluate if their similar toxicities are observed in ESCC patients with variants in the FA genes who are treated with these agents.…”

Section: Discussionmentioning

confidence: 99%

Mutations in Fanconi anemia genes and the risk of esophageal cancer

et al. 2011

View full text Add to dashboard Cite

The incidence of esophageal squamous cell carcinoma (ESCC) is very high in northeastern Iran. Previously, we reported a strong familial component of ESCC among Turkmens, who constitute approximately one-half of the population of this region. We hypothesized that the genes which cause Fanconi anemia might be candidate genes for ESCC. We sequenced the entire coding regions of 12 Fanconi anemia genes in the germline DNA of 190 Turkmen cases of ESCC. We identified three heterozygous insertion/deletion mutations: one in FANCD2 (p.Val1233del), one in FANCE (p.Val311SerfsX2), and one in FANCL (p.Thr367AsnfsX13). All three patients had a strong family history of ESCC. In addition, four patients (out of 746 tested) were homozygous for the FANCA p.Ser858Arg mutation, compared to none of 1,373 matched controls (OR = 16.7, 95% CI = 6.2-44.2, P = 0.01). The p. Lys3326X mutation in BRCA2 (also known as Fanconi anemia gene FANCD1) was present in 27 of 746 ESCC cases and in 16 of 1,373 controls (OR = 3.38, 95% CI = 1.97-6.91, P = 0.0002). In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.

show abstract

Section: Discussionmentioning

confidence: 99%

Mutations in Fanconi anemia genes and the risk of esophageal cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In recent decades, there has been a dramatic epidemiological shift in the incidence of esophageal adenocarcinoma (EAC), with rates rising by 600% over the last 30 years in Western populations (1 3 Christian N Paxton, 4 Katherine Geiersbach, 4,5 Mary P Bronner, 4,5 Jacintha O'Sullivan, 1 John V Reynolds, 1 and Stephen G Maher Esophageal adenocarcinoma (EAC) has a poor prognosis and is increasing in incidence in many Western populations. Neoadjuvant chemoradiation therapy (CRT) followed by surgery is increasingly the standard of care for locally advanced EAC; however, resistance to treatment is a significant clinical problem.…”

Section: Introductionmentioning

confidence: 99%

“…chemoradiation therapy (CRT) followed by surgery increasingly becoming the standard of care in Ireland, North America and several European centers (4).…”

mentioning

confidence: 99%

Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma

Lynam‐Lennon

Bibby

Mongan

et al. 2016

Mol Med

Self Cite

View full text Add to dashboard Cite

“…Oof the two main histological types – adenocarcinoma (AC) and squamous cell carcinoma (ESCC) – the latter is still the most prevalent one in developing countries . Single modality treatments, multimodal treatments, and palliative treatments are established methods for disease management .…”

mentioning

confidence: 99%

Nuclear, cytoplasmic, and stromal expression of ZEB1 in squamous and small cell carcinoma of the esophagus

Goscinski

Zhou

et al. 2015

APMIS

View full text Add to dashboard Cite

Zinc finger E-box-binding homeobox 1 (ZEB1) is a transcriptional factor known to repress E-cadherin promoter and thus induce EMT. Expression of ZEB-1 has in numerous cancers been associated with aggressive disease and poor clinical outcome. Our aim was to investigate the expression of ZEB1 in esophageal squamous- and small-cell carcinomas. Immunohistochemical staining was performed on tissue sections obtained from 151 patients with esophageal squamous cell carcinoma (ESCC) and 25 patients with primary small-cell carcinoma of the esophagus (PSCCE). Semi-quantitative analysis, and thus statistical analysis, has been accomplished on the samples. Immunohistochemistry revealed ZEB1 expression in the cytoplasm (64.9% of cases), in nuclei (11.3% of cases) and in tumor stroma (80.1% of cases) of ESCC. In PSCCE only nuclear staining (88.0% of cases) was observed. Weak cytoplasmic expression of ZEB1 in ESCC was associated with longer survival. Immunohistochemical evaluation of ZEB1 cytoplasmic expression in ESCC may have clinical prognostic value, but further studies are needed to fully understand the function as well as potential clinical and therapeutic implications of ZEB1 expression in cancers.

show abstract

Treatment options for esophageal cancer

Cited by 9 publications

References 104 publications

Mutations in Fanconi anemia genes and the risk of esophageal cancer

Mutations in Fanconi anemia genes and the risk of esophageal cancer

Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma

Nuclear, cytoplasmic, and stromal expression of ZEB1 in squamous and small cell carcinoma of the esophagus

Contact Info

Product

Resources

About